For the twelve months ended Sep 30, 2026, Bio-Techne Corp reported $1.23B of revenue and $171.95M of net income.
TECH revenue was $299.71M in fiscal Q1 2027 (ended Sep 30, 2026), up 4.6% from a year earlier and down 6.7% from the prior quarter. For the full fiscal 2026 it was $1.22B, down 0.4% from fiscal 2025. Compound annual growth was +5.5% over 5 years and +9.3% over 10 years. It rose in 9 of the last 10 fiscal years.
TECH net income was $28.29M in fiscal Q1 2027 (ended Sep 30, 2026), down 25.9% from a year earlier and down 48.2% from the prior quarter. For the full fiscal 2026 it was $181.84M, up 147.9% from fiscal 2025. Compound annual growth was +5.3% over 5 years and +5.7% over 10 years. It rose in 5 of the last 10 fiscal years.
TECH diluted EPS was $0.18 in fiscal Q1 2027 (ended Sep 30, 2026), down 25.0% from a year earlier and down 50.0% from the prior quarter. For the full fiscal 2026 it was $1.16, up 152.2% from fiscal 2025. Compound annual growth was +5.9% over 5 years and +5.2% over 10 years.
TECH free cash flow was $67.20M in fiscal Q1 2027 (ended Sep 30, 2026), up 202.4% from a year earlier and down 22.7% from the prior quarter. For the full fiscal 2026 it was $263.22M, up 2.6% from fiscal 2025. Compound annual growth was -3.1% over 5 years and +7.5% over 10 years. It rose in 7 of the last 10 fiscal years.
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.22B | $1.16B | $1.14B | $1.11B | $931.03M | $738.69M | $714.01M | $642.99M | $563.00M |
| Cost of revenue | $415.97M | $429.36M | $389.33M | $366.89M | $349.10M | $298.18M | $255.50M | $240.51M | $210.85M | $188.46M |
| Gross profit | $799.07M | $790.27M | $769.73M | $769.82M | $756.50M | $632.85M | $483.19M | $473.49M | $432.14M | $374.54M |
| Research and development | $94.77M | $99.50M | $96.66M | $92.49M | $87.14M | $70.60M | $65.19M | $62.41M | $55.33M | $53.51M |
| Selling, general and admin | $452.42M | $588.52M | $466.38M | $378.38M | $372.77M | $324.95M | $260.58M | $264.36M | $240.64M | $200.44M |
| Operating income | $251.89M | $102.25M | $206.69M | $298.94M | $296.59M | $237.30M | $157.42M | $146.72M | $136.18M | $120.58M |
| Interest expense | $9.63M | $8.51M | $15.74M | $11.21M | $11.31M | $13.95M | $19.20M | $21.70M | $10.19M | $7.36M |
| Pre-tax income | $240.68M | $98.46M | $185.69M | $338.66M | $301.39M | $148.18M | $276.48M | $112.02M | $125.95M | $111.96M |
| Income tax | $58.82M | $25.06M | $17.58M | $53.22M | $38.29M | $8.59M | $47.18M | $15.94M | -$198.0K | $35.88M |
| Net income | $181.84M | $73.36M | $168.07M | $285.26M | $272.05M | $140.41M | $229.30M | $96.07M | $126.15M | $76.09M |
| EPS, basic | $1.17 | $0.47 | $1.07 | $1.81 | $1.73 | $0.91 | $1.50 | $0.64 | $0.84 | $0.51 |
| EPS, diluted | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.46 | $0.62 | $0.83 | $0.51 |
| Diluted shares | 157.0M | 159.7M | 160.8M | 161.9M | 164.1M | 161.9M | 157.6M | 155.6M | 152.2M | 150.0M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $264.71M | $162.19M | $151.79M | $180.57M | $172.57M | $199.09M | $146.63M | $100.89M | $121.99M | $91.61M |
| Short-term investments | - | - | $1.07M | $23.74M | $74.46M | - | - | - | - | - |
| Receivables | $216.59M | $206.88M | $241.39M | $218.47M | $194.55M | $145.38M | $122.53M | $137.47M | $120.30M | $116.83M |
| Inventory | $195.74M | $189.45M | $179.73M | $171.64M | $141.12M | $116.75M | $103.15M | $91.05M | $85.65M | $85.65M |
| Current assets | $744.40M | $608.30M | $617.42M | $621.48M | $605.56M | $510.61M | $520.92M | $412.61M | $398.37M | $348.02M |
| Goodwill | $975.36M | $980.93M | $972.66M | $872.74M | $822.10M | $843.07M | $728.31M | $732.67M | $597.89M | $579.03M |
| Total assets | $2.59B | $2.56B | $2.70B | $2.64B | $2.29B | $2.26B | $2.03B | $1.88B | $1.59B | $1.56B |
| Current liabilities | $163.70M | $175.85M | $159.38M | $128.51M | $176.02M | $152.28M | $106.67M | $101.98M | $79.51M | $135.52M |
| Short-term debt | - | - | - | - | $12.50M | $12.50M | $12.50M | $12.50M | - | - |
| Long-term debt | $200.00M | $346.00M | $319.00M | $350.00M | $243.41M | $328.83M | $344.24M | $492.66M | $339.00M | $343.77M |
| Total debt | $200.00M | $346.00M | $319.00M | $350.00M | $255.91M | $341.33M | $356.74M | $505.16M | $339.00M | $343.77M |
| Total liabilities | - | $639.06M | $635.02M | $672.18M | $593.79M | $691.72M | $646.40M | $718.82M | $514.14M | - |
| Shareholders' equity | $2.11B | $1.92B | $2.07B | $1.97B | $1.70B | $1.57B | $1.38B | $1.17B | $1.08B | $949.63M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $292.07M | $287.56M | $298.98M | $254.39M | $325.27M | $352.16M | $205.22M | $181.62M | $170.37M | $143.72M |
| Capital expenditures | $28.85M | $31.01M | $62.88M | $38.24M | $44.91M | $44.30M | $51.74M | $25.41M | $20.93M | $15.18M |
| Free cash flow | $263.22M | $256.55M | $236.10M | $216.15M | $280.36M | $307.86M | $153.47M | $156.21M | $149.43M | $128.54M |
| Investing cash flow | -$18.19M | -$35.18M | -$203.03M | -$265.65M | -$96.85M | -$243.52M | $27.09M | -$336.80M | -$38.71M | -$305.95M |
| Financing cash flow | -$169.11M | -$253.91M | -$122.40M | $22.62M | -$242.85M | -$62.55M | -$183.80M | $134.38M | -$99.19M | $189.11M |
| Dividends paid | $49.92M | $50.39M | $50.42M | $50.28M | $50.19M | $49.62M | $48.90M | $48.36M | $47.97M | $47.33M |
| Share repurchases | $41.67M | $275.73M | $80.04M | $19.56M | $160.95M | $43.18M | $50.11M | $15.40M | $0 | - |
| Stock-based compensation | $41.37M | $40.83M | $38.04M | $39.23M | $42.18M | $48.98M | $32.37M | $32.28M | $28.24M | $14.63M |
| Depreciation and amortization | $97.36M | $109.90M | $111.71M | $107.24M | $101.07M | $87.75M | $82.74M | $78.17M | $64.46M | $60.04M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -0.4% | 5.2% | 2.0% | 2.8% | 18.7% | 26.0% | 3.5% | 11.0% | 14.2% | 12.8% |
| Net income growth, YoY | 147.9% | -56.4% | -41.1% | 4.9% | 93.8% | -38.8% | 138.7% | -23.8% | 65.8% | -27.2% |
| EPS growth, YoY | 152.2% | -56.2% | -40.3% | 6.0% | 90.8% | -40.2% | 135.6% | -25.4% | 63.1% | -27.5% |
| Gross margin | 65.8% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% |
| Operating margin | 20.7% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 20.5% | 21.2% | 21.4% |
| Net margin | 15.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.6% | 13.5% |
| Free cash flow margin | 21.7% | 21.0% | 20.4% | 19.0% | 25.4% | 33.1% | 20.8% | 21.9% | 23.2% | 22.8% |
| Return on equity | 8.6% | 3.8% | 8.1% | 14.5% | 16.0% | 8.9% | 16.6% | 8.2% | 11.7% | 8.0% |
| Return on assets | 7.0% | 2.9% | 6.2% | 10.8% | 11.9% | 6.2% | 11.3% | 5.1% | 7.9% | 4.9% |
| Current ratio | 4.55 | 3.46 | 3.87 | 4.84 | 3.44 | 3.35 | 4.88 | 4.05 | 5.01 | 2.57 |
| Debt to equity | 0.09 | 0.18 | 0.15 | 0.18 | 0.15 | 0.22 | 0.26 | 0.43 | 0.31 | 0.36 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $299.71M | $321.19M | $311.42M | $295.88M | $286.56M | $316.96M | $316.18M | $297.03M | $289.46M | $306.10M | $303.43M | $272.60M |
| Cost of revenue | $103.09M | $109.80M | $103.13M | $104.60M | $98.44M | $118.15M | $101.63M | $103.14M | $106.44M | $102.75M | $98.83M | $96.01M |
| Gross profit | $196.62M | $211.39M | $208.29M | $191.28M | $188.11M | $198.81M | $214.56M | $193.89M | $183.02M | $203.35M | $204.60M | $176.59M |
| Research and development | $26.34M | $23.95M | $23.45M | $23.13M | $24.24M | $26.03M | $24.58M | $25.02M | $23.87M | $23.99M | $25.76M | $22.92M |
| Selling, general and admin | $133.68M | $113.17M | $109.34M | $113.69M | $116.21M | $196.64M | $151.27M | $121.45M | $119.16M | $133.54M | $111.84M | $115.67M |
| Operating income | $36.60M | $74.28M | $75.50M | $54.46M | $47.66M | -$23.86M | $38.71M | $47.42M | $39.99M | $45.82M | $67.00M | $38.00M |
| Interest expense | $2.17M | $2.12M | $2.40M | $2.17M | $2.93M | $2.18M | $2.01M | $2.15M | $2.18M | $2.51M | $4.00M | $4.33M |
| Pre-tax income | $34.69M | $70.68M | $71.22M | $50.78M | $47.99M | -$22.86M | $38.27M | $42.88M | $40.17M | $41.66M | $61.08M | $33.39M |
| Income tax | $6.40M | $16.06M | $20.18M | $12.78M | $9.81M | -$5.18M | $15.69M | $7.99M | $6.57M | $1.07M | $12.03M | $5.92M |
| Net income | $28.29M | $54.60M | $51.05M | $38.01M | $38.19M | -$17.71M | $22.59M | $34.89M | $33.60M | $40.55M | $49.06M | $27.46M |
| EPS, basic | $0.18 | $0.35 | $0.33 | $0.24 | $0.25 | -$0.10 | $0.14 | $0.22 | $0.21 | $0.27 | $0.31 | $0.17 |
| EPS, diluted | $0.18 | $0.36 | $0.32 | $0.24 | $0.24 | -$0.11 | $0.14 | $0.22 | $0.21 | $0.26 | $0.31 | $0.17 |
| Diluted shares | 157.9M | - | 157.4M | 157.0M | 156.4M | - | 158.9M | 160.6M | 161.1M | - | 160.5M | 160.1M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $350.04M | $264.71M | $209.82M | $172.88M | $144.96M | $162.19M | $140.67M | $177.55M | $187.54M | $151.79M | $139.91M | $130.13M |
| Short-term investments | - | - | - | - | - | - | $0 | $0 | - | $1.07M | $5.40M | $5.52M |
| Receivables | $203.06M | $216.59M | $214.56M | $184.61M | $183.90M | $206.88M | $237.14M | $217.94M | $223.69M | $241.39M | $227.89M | $207.45M |
| Inventory | $197.67M | $195.74M | $201.18M | $205.45M | $203.19M | $189.45M | $191.08M | $188.37M | $185.04M | $179.73M | $179.50M | $180.84M |
| Current assets | $824.83M | $744.40M | $688.05M | $637.43M | $609.51M | $608.30M | $627.24M | $634.64M | $648.57M | $617.42M | $610.65M | $590.64M |
| Goodwill | $972.07M | $975.36M | $977.80M | $980.56M | $978.91M | $980.93M | $968.61M | $964.61M | $982.59M | $972.66M | $970.97M | $980.08M |
| Total assets | $2.64B | $2.59B | $2.55B | $2.52B | $2.53B | $2.56B | $2.64B | $2.67B | $2.74B | $2.70B | $2.72B | $2.73B |
| Current liabilities | $361.27M | $163.70M | $153.28M | $140.43M | $144.54M | $175.85M | $169.20M | $161.26M | $142.13M | $159.38M | $149.82M | $135.23M |
| Short-term debt | $200.00M | - | - | - | - | - | - | - | - | - | - | - |
| Long-term debt | - | $200.00M | $200.00M | $260.00M | $300.00M | $346.00M | $330.00M | $300.00M | $300.00M | $319.00M | $389.00M | $447.00M |
| Total debt | - | $200.00M | $200.00M | $260.00M | $300.00M | $346.00M | $330.00M | $300.00M | $300.00M | $319.00M | $389.00M | $447.00M |
| Total liabilities | - | - | $465.30M | $511.71M | $560.33M | $639.06M | $626.23M | $591.93M | $597.37M | $635.02M | $706.79M | $767.19M |
| Shareholders' equity | $2.17B | $2.11B | $2.09B | $2.01B | $1.97B | $1.92B | $2.02B | $2.08B | $2.14B | $2.07B | $2.01B | $1.96B |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $73.11M | $95.42M | $86.66M | $82.41M | $27.59M | $98.20M | $41.12M | $84.35M | $63.89M | $75.50M | $80.99M | $83.12M |
| Capital expenditures | $5.92M | $8.48M | $9.09M | $5.92M | $5.36M | $4.89M | $10.12M | $6.82M | $9.17M | $17.98M | $16.44M | $14.86M |
| Free cash flow | $67.20M | $86.94M | $77.58M | $76.49M | $22.22M | $93.31M | $31.00M | $77.53M | $54.72M | $57.52M | $64.55M | $68.25M |
| Investing cash flow | -$3.93M | -$7.06M | -$5.82M | -$5.92M | $605.0K | $406.0K | -$8.87M | -$5.03M | -$21.68M | -$8.81M | -$16.44M | -$23.67M |
| Financing cash flow | $16.39M | -$33.21M | -$42.72M | -$48.99M | -$44.20M | -$90.45M | -$68.05M | -$83.84M | -$11.57M | -$60.09M | -$52.42M | -$81.40M |
| Dividends paid | $12.56M | $12.48M | $12.52M | $12.47M | $12.44M | $12.39M | $12.58M | $12.74M | $12.69M | $12.63M | $12.58M | $12.56M |
| Share repurchases | - | $41.65M | $0 | $0 | $24.0K | $100.06M | $100.05M | - | - | $0 | $0 | - |
| Stock-based compensation | $13.41M | $5.23M | $10.49M | $13.96M | $11.68M | $4.55M | $11.39M | $14.71M | $10.18M | $7.06M | $8.13M | $12.75M |
| Depreciation and amortization | $23.73M | $24.14M | $24.17M | $24.71M | $24.34M | $27.11M | $27.57M | $27.08M | $28.14M | $28.06M | $27.31M | $27.80M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 4.6% | 1.3% | -1.5% | -0.4% | -1.0% | 3.5% | 4.2% | 9.0% | 4.5% | 1.6% | 3.2% | 0.4% |
| Net income growth, YoY | -25.9% | - | 126.0% | 8.9% | 13.6% | - | -54.0% | 27.0% | -34.1% | -46.3% | -30.1% | -45.1% |
| EPS growth, YoY | -25.0% | - | 128.6% | 9.1% | 14.3% | - | -54.8% | 29.4% | -32.3% | -44.7% | -27.9% | -45.2% |
| Gross margin | 65.6% | 65.8% | 66.9% | 64.6% | 65.6% | 62.7% | 67.9% | 65.3% | 63.2% | 66.4% | 67.4% | 64.8% |
| Operating margin | 12.2% | 23.1% | 24.2% | 18.4% | 16.6% | -7.5% | 12.2% | 16.0% | 13.8% | 15.0% | 22.1% | 13.9% |
| Net margin | 9.4% | 17.0% | 16.4% | 12.8% | 13.3% | -5.6% | 7.1% | 11.7% | 11.6% | 13.2% | 16.2% | 10.1% |
| Free cash flow margin | 22.4% | 27.1% | 24.9% | 25.9% | 7.8% | 29.4% | 9.8% | 26.1% | 18.9% | 18.8% | 21.3% | 25.0% |
| Current ratio | 2.28 | 4.55 | 4.49 | 4.54 | 4.22 | 3.46 | 3.71 | 3.94 | 4.56 | 3.87 | 4.08 | 4.37 |
| Debt to equity | - | 0.09 | 0.10 | 0.13 | 0.15 | 0.18 | 0.16 | 0.14 | 0.14 | 0.15 | 0.19 | 0.23 |
Source: XBRL data Bio-Techne Corp files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 4-for-1, first reported Feb 7, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TECH | $1.23B | +0.9% | $171.95M | 14.0% | $11.41B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |